

Ministry of Health

Health Programs and Delivery Division

## Drug Submission Status

Report for August 2023

### Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	2 mg	tablet	02534320
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	5 mg	tablet	02534339
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	10 mg	tablet	02534347
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	15 mg	tablet	02534355
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	20 mg	tablet	02534363
Sivem Pharmaceuticals	Aripiprazole	Abilify	ARIPIPRAZOLE	30 mg	tablet	02534371
Nora Pharma	NRA-Mirtazapine	Remeron	MIRTAZAPINE	30 mg	tablet	02534932

Auro Pharma Inc.	Hydralazine Hydrochloride Injection, USP	Apresoline	HYDRALAZINE HCL	20 mg/mL	solution (intravenous)	02516160
------------------	--	------------	-----------------	----------	---------------------------	----------